The Shkreli Pill

The only pill worth swallowing. Markets, memes, medicine, and mayhem — served straight, no chaser.Watch the video versions on YouTube : https://www.youtube.com/@TheShkreliPill/videos.

The Shkreli Pill is a business podcast hosted by Urban Tapes, with 242 episodes on record and a Required Pod Score of 80.

Urban Tapes hosts The Shkreli Pill, a business show with 242 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  The Shkreli Pill

  Episode 1044: Massive Squeeze on Moderna, Why SanDisk and Micron Are Falling Fast

  Sep 24, 202625 min

  In this episode, Martin discusses a sharp move in Moderna and examines the market dynamics behind what he describes as a major short squeeze. He also breaks down the declines in SanDisk and Micron, exploring memory pricing, semiconductor-cycle expectations, supply and demand, valuation, and changing investor sentiment while explaining the factors shaping his outlook on the memory sector.

  ListenShow Notes
• 

  The Shkreli Pill

  Episode 1043: Martin Shkreli Explains Why He Is Bearish On Quantum Computing

  Sep 24, 202612 min

  In this episode, Martin explains why he remains skeptical of the investment case for quantum computing and outlines the reasoning behind his bearish outlook on the sector. He discusses technological limitations, commercialization timelines, competitive dynamics, valuations, and investor expectations, examining whether current quantum computing stocks adequately reflect the risks and uncertainty surrounding the industry’s long-term development.

  ListenShow Notes
• 

  The Shkreli Pill

  Episode 1042: Nidec Is Winning the AI Surge, I Sold My Tech Stocks for AbbVie, Lam Research (LRCX)

  Sep 23, 202631 min

  In this episode, Martin discusses why he believes Nidec is positioned to benefit from the continued expansion of AI infrastructure and data centers. He also explains his decision to reduce exposure to technology stocks in favor of AbbVie, examining the pharmaceutical company’s valuation and growth outlook, before analyzing Lam Research (LRCX) and the opportunities and risks surrounding semiconductor equipment demand and the broader chip cycle.

  ListenShow Notes
• 

  The Shkreli Pill

  Episode 1040: AMD Is a $1 Trillion Bubble, Ozempic Is About to Collapse, Novo Nordisk Stock

  Sep 22, 202625 min

  In this episode, Martin lays out his bearish thesis on AMD and explains why he believes expectations surrounding AI growth have pushed its valuation to unsustainable levels. He also discusses the outlook for Ozempic and the increasingly competitive GLP-1 drug market, analyzing Novo Nordisk’s pipeline, market position, valuation, and the risks he believes could challenge its future growth.

  ListenShow Notes
• 

  The Shkreli Pill

  Episode 1039: How Wall Street Hides Data from Retail, Silicon Valley's Effective Altruism

  Sep 21, 202632 min

  In this episode, Martin discusses the information gap between institutional and retail investors, examining how access to specialized datasets, research tools, and market intelligence can create advantages on Wall Street. He also explores effective altruism in Silicon Valley, discussing its ideas, influence, and the incentives surrounding the movement while sharing his perspective on how wealth, technology, and philanthropy intersect.

  ListenShow Notes

Recent guests on The Shkreli Pill. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.